LOXL2 and neoplasm: Although our findings demonstrated that CD8+ T cells were indispensable for combination treatment efficacy, the decrease in exhausted CD8+ T cells from LOXL2 inhibition or knockdown did not fully characterize the observed phenotype as the addition of PD-(L)1 blockade was still required for tumor growth reduction.